Chemomab Therapeutics (CMMB) Return on Assets (2019 - 2025)

Chemomab Therapeutics' Return on Assets history runs 7 years deep, the most recent figure standing at 477.99% for Q4 2025.

• Quarterly Return on Assets rose 27876.0% year-over-year to 477.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 477.99% (up 27876.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
• Return on Assets was 477.99% for Q4 2025 at Chemomab Therapeutics, up from 321.01% in the prior quarter.
• Across five years, Return on Assets topped out at 477.99% in Q4 2025 and bottomed at 0.0% in Q1 2021.
• A 5-year average of 78.32% and a median of 0.01% in 2023 frame the typical range for Return on Assets.
• Annual changes were most pronounced in 2022 — Return on Assets changed 0 bps — and 2025, when it soared 32100 bps.
• Chemomab Therapeutics' Return on Assets stood at 0.0% in 2021, then soared by 310 bps to 0.0% in 2022, then soared by 168 bps to 0.01% in 2023, then surged by 1873995 bps to 199.23% in 2024, then soared by 140 bps to 477.99% in 2025.
• Business Quant data shows CMMB's Return on Assets at 477.99% in Q4 2025, 321.01% in Q3 2025, and 314.96% in Q2 2025.